Devyser Diagnostics (OL0) Stock Overview
Engages in the development, manufacture, and sale of diagnostic kits and solutions for DNA testing within hereditary diseases, oncology, and post-transplantation monitoring in Sweden, rest of Europe, the Middle East, Africa, North and South America, and Asia. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for OL0 from our risk checks.
OL0 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
100% Patient Improvement in trial puts this $16M Biotech on the radar
Key Takeaways Hoth is a clinical-stage biotech with a diversified pipeline across oncology, neurology, and inflammation. Lead drug HT-001 targets cancer treatment related rashes, a multi-hundred-million-dollar niche where no approved therapies exist.
Devyser Diagnostics AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 12.50 |
| 52 Week High | SEK 14.20 |
| 52 Week Low | SEK 7.61 |
| Beta | 0.75 |
| 1 Month Change | -5.02% |
| 3 Month Change | 9.84% |
| 1 Year Change | 15.74% |
| 3 Year Change | 104.92% |
| 5 Year Change | n/a |
| Change since IPO | 48.42% |
Recent News & Updates
Recent updates
Shareholder Returns
| OL0 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0.3% | 0.2% | 2.7% |
| 1Y | 15.7% | -29.1% | 14.6% |
Return vs Industry: OL0 exceeded the German Biotechs industry which returned -29.1% over the past year.
Return vs Market: OL0 exceeded the German Market which returned 14.6% over the past year.
Price Volatility
| OL0 volatility | |
|---|---|
| OL0 Average Weekly Movement | 5.9% |
| Biotechs Industry Average Movement | 10.0% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 12.3% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: OL0 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: OL0's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 118 | Jan Wahlstrom | devyser.com |
Devyser Diagnostics AB (publ) engages in the development, manufacture, and sale of diagnostic kits and solutions for DNA testing within hereditary diseases, oncology, and post-transplantation monitoring in Sweden, rest of Europe, the Middle East, Africa, North and South America, and Asia. The company offers products in the areas of post-transplantation; thalassemia; breast, colorectal, and ovarian cancer; non-invasive fetal RHD screening prenatal testing, hereditary, cystic fibrosis, cardiovascular, male infertility, and rapid aneuploidy analysis, as well as accessories. Its products are used for targeted cancer treatment to diagnosis genetic diseases and transplant patient follow-up.
Devyser Diagnostics AB (publ) Fundamentals Summary
| OL0 fundamental statistics | |
|---|---|
| Market cap | €213.69m |
| Earnings (TTM) | -€4.16m |
| Revenue (TTM) | €21.38m |
Is OL0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OL0 income statement (TTM) | |
|---|---|
| Revenue | SEK 235.10m |
| Cost of Revenue | SEK 43.30m |
| Gross Profit | SEK 191.80m |
| Other Expenses | SEK 237.50m |
| Earnings | -SEK 45.70m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
Nov 05, 2025
| Earnings per share (EPS) | -2.75 |
| Gross Margin | 81.58% |
| Net Profit Margin | -19.44% |
| Debt/Equity Ratio | 0.1% |
How did OL0 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/05 02:24 |
| End of Day Share Price | 2025/10/03 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Devyser Diagnostics AB (publ) is covered by 6 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Erik Hultgård | Carnegie Investment Bank AB |
| Erik Hultgård | DNB Carnegie |
| Ludvig Lundgren | Nordea Markets |